Creative Planning’s Aldeyra Therapeutics ALDX Stock Holding History

Creative Planning’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.8K	Sell	28,871 -5,650	-16%	-$24.8K	﹤0.01%	3986
2025 Q4	$179K	Sell	34,521 -327	-0.9%	-$1.68K	﹤0.01%	3589
2025 Q3	$182K	Buy	34,848 +22,801	+189%	+$119K	﹤0.01%	3527
2025 Q2	$46.1K	Sell	12,047 -970	-7%	-$2.51K	﹤0.01%	3530
2025 Q1	$74.8K	Buy	+13,017	New	+$76.9K	﹤0.01%	3295
2024 Q2	–	Sell	-10,686	Closed	-$34.9K	–	3070
2024 Q1	$34.9K	Buy	+10,686	New	+$35.2K	﹤0.01%	2810

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Creative Planning's ALDX Position: Q1 2026 in Review

Creative Planning reduced its Aldeyra Therapeutics (ALDX) stake by 16% in Q1 2026, selling an estimated $24.8K and leaving 28,871 shares worth $48.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3986.

Creative Planning first reported a position in ALDX in Q1 2024 and has held it in 6 quarters since. The position peaked at $182K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Creative Planning held 28,871 shares of Aldeyra Therapeutics worth $48.8K as of Q1 2026.
Creative Planning sold 5,650 Aldeyra Therapeutics shares in Q1 2026, an estimated $24.8K.
Aldeyra Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3986 holding.
Creative Planning first reported a position in Aldeyra Therapeutics in Q1 2024 and has held it in 6 quarters since.
Creative Planning's Aldeyra Therapeutics position peaked at $182K in Q3 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.